Psoriasis Trial, Recruiting NCT07234591 Sponsor: Usynova Pharmaceuticals Ltd. Condition: Psoriasis
Back to Psoriasis

Psoriasis Trial, Recruiting

NCT07234591
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 70 years, of any gender
  • People who weigh more than 40 kg and have a body mass index (BMI) between 18 and 40 (a measure of body weight relative to height)
  • People who have been diagnosed with plaque psoriasis (a skin condition causing scaly patches) for at least 6 months before the start of the trial
  • Women who could become pregnant, and sexually active men, must agree to use an approved method of contraception during the trial

Who may not be able to join:

  • People who have been diagnosed with a type of psoriasis other than plaque psoriasis
  • People who have previously received a type of medication called a TYK2 inhibitor (confirm with trial site for specific drug names)
  • People who have previously received certain psoriasis treatments — including biological therapies, immune-regulating drugs, or hormonal treatments — within a set period before the trial, if the trial doctor believes this could affect the immune system
  • People who have taken part in another clinical trial within the past 30 days, or within 5 half-lives of the previous trial drug, or who are still attending visits for another clinical trial
  • People who have a long-term illness that could affect the study, or who have serious infectious diseases — including a history of tuberculosis that was not fully treated, serious bone or joint infections within the past 6 months, or other acute infections
  • People who have a known or suspected skin or immune system condition other than psoriasis or psoriatic arthritis
  • People who have other health conditions that the trial doctor considers unsuitable for participation (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +8613636393195

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Usynova Pharmaceuticals Ltd.
Registry
ClinicalTrials.gov
Start date
21 October 2025
Est. completion
30 April 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The Percentage of Participants Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov